SNY Sanofi American Depositary Shares (Each representing one-half of one ordinary share) Loading... : Bullish and Bearish Analyst Opinions
From MRNA earnings callsLoading chart...
Top Calls
Feed
12:00
Jul 31
Jul 31
Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches. — A late strain update capability could allow Moderna to offer a better-matched vaccine in a given season, potentially shifting market share from incumbent flu vaccine makers.
MED
13:00
Feb 13
Feb 13
The European respiratory vaccine market (approx. $1.8 billion) is opening up to Moderna in 2027, as a competitor's pandemic contract expires, allowing Moderna to launch multiple products and challenge incumbent players. — This opens a major new market for Moderna, directly competing with established players like Pfizer, GSK, and Sanofi, potentially disrupting their respiratory franchise revenues.
MED
About SNY Analyst Coverage
Buzzberg tracks SNY (Sanofi American Depositary Shares (Each representing one-half of one ordinary share)) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Stephen Hoge, Stéphane Boncel.